Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis
Aim. Comparative efficacy analysis of autologous hematopoietic stem cells (HSC) prior to auto-HSCT in patients with lymphoproliferative disorders (LPDs) and multiple sclerosis (MS). Materials & Methods. The trial included 237 patients: 103 LPD and 134 MS patients. In 225 patients HSC mobiliza...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2018-12-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2018/12/7-1.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768017487986688 |
|---|---|
| author | OV Fedyk VO Sarzhevskii DA Fedorenko VYa Mel’nichenko YuN Dubinina NE Mochkin EG Smirnova DS Kolesnikova AE Bannikova |
| author_facet | OV Fedyk VO Sarzhevskii DA Fedorenko VYa Mel’nichenko YuN Dubinina NE Mochkin EG Smirnova DS Kolesnikova AE Bannikova |
| author_sort | OV Fedyk |
| collection | DOAJ |
| description | Aim. Comparative efficacy analysis of autologous hematopoietic stem cells (HSC) prior to auto-HSCT in patients with lymphoproliferative disorders (LPDs) and multiple sclerosis (MS).
Materials & Methods. The trial included 237 patients: 103 LPD and 134 MS patients. In 225 patients HSC mobilization involved only colony-stimulating factors (CSFs), in 12 patients chemotherapy (cyclophosphamide, etoposide) was combined with CSFs. On the intended date of cytapheresis all the patients were tested for CD34+ marker expression. Сytapheresis followed in the patients with CD34+ count more than 0.01 × 106/mL.
Results. In 23 (22 %) LPD patients CD34+ count was too low for auto-HSCT (‘collection failure group’). Within this group 19 patients received CSF mobilization, and 4 patients received chemotherapy + CSF. Plerixafor was administered in 5 patients, in 4 of them a repeated mobilization also failed to collect enough cells. In 80 LPD patients the number of mobilized and collected CD34+ cells was sufficient for auto-HSCT (‘collection success group’). Within this group 77 patients received auto-HSCT, 74 patients were treated with CSF mobilization, 6 patients received chemotherapy + CSF, and in 11 patients plerixafor was administered. Median total number of CD34+ cells in the ‘collection success group’ was 2.7 × 106/kg. All 134 MS patients had enough CD34+ cells for auto-HSCT. All of them received CSF mobilization. Median total number of CD34+ cells in the MS group was 2.34 × 106/kg. Potential risk factors for HSC mobilization failure in LPDs were evaluated. They included age, gender, prior radiotherapy, number of antitumor treatment lines prior to auto-HSCT, clinical response prior to auto-HSCT (complete/partial remission or stabilization), and HSC mobilization regimen. These factors with the exception of gender were not associated with mobilization failure parameters. The worst mobilization outcomes were reported in male patients.
Conclusion. In 22 % of LPD patients the planned high-dose chemotherapy and auto-HSCT failed due to insufficient counts of autologous CD34+ cells in apheresis product. Male gender can be considered to be a prognostic factor of mobilization failure in LPDs. |
| format | Article |
| id | doaj-art-6eb663a3a2a144d789613f8820d38db2 |
| institution | DOAJ |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2018-12-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-6eb663a3a2a144d789613f8820d38db22025-08-20T03:03:58ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392018-12-01121515810.21320/2500-2139-2019-12-1-51-58Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple SclerosisOV Fedyk0VO Sarzhevskii1DA Fedorenko2VYa Mel’nichenko3YuN Dubinina4NE Mochkin5 EG Smirnova6DS Kolesnikova7 AE Bannikova8NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203Aim. Comparative efficacy analysis of autologous hematopoietic stem cells (HSC) prior to auto-HSCT in patients with lymphoproliferative disorders (LPDs) and multiple sclerosis (MS). Materials & Methods. The trial included 237 patients: 103 LPD and 134 MS patients. In 225 patients HSC mobilization involved only colony-stimulating factors (CSFs), in 12 patients chemotherapy (cyclophosphamide, etoposide) was combined with CSFs. On the intended date of cytapheresis all the patients were tested for CD34+ marker expression. Сytapheresis followed in the patients with CD34+ count more than 0.01 × 106/mL. Results. In 23 (22 %) LPD patients CD34+ count was too low for auto-HSCT (‘collection failure group’). Within this group 19 patients received CSF mobilization, and 4 patients received chemotherapy + CSF. Plerixafor was administered in 5 patients, in 4 of them a repeated mobilization also failed to collect enough cells. In 80 LPD patients the number of mobilized and collected CD34+ cells was sufficient for auto-HSCT (‘collection success group’). Within this group 77 patients received auto-HSCT, 74 patients were treated with CSF mobilization, 6 patients received chemotherapy + CSF, and in 11 patients plerixafor was administered. Median total number of CD34+ cells in the ‘collection success group’ was 2.7 × 106/kg. All 134 MS patients had enough CD34+ cells for auto-HSCT. All of them received CSF mobilization. Median total number of CD34+ cells in the MS group was 2.34 × 106/kg. Potential risk factors for HSC mobilization failure in LPDs were evaluated. They included age, gender, prior radiotherapy, number of antitumor treatment lines prior to auto-HSCT, clinical response prior to auto-HSCT (complete/partial remission or stabilization), and HSC mobilization regimen. These factors with the exception of gender were not associated with mobilization failure parameters. The worst mobilization outcomes were reported in male patients. Conclusion. In 22 % of LPD patients the planned high-dose chemotherapy and auto-HSCT failed due to insufficient counts of autologous CD34+ cells in apheresis product. Male gender can be considered to be a prognostic factor of mobilization failure in LPDs.http://bloodjournal.ru/wp-content/uploads/2018/12/7-1.pdflymphoproliferative disordersautologous transplantationmobilization of peripheral blood stem cellsautoimmune diseasesmultiple sclerosis |
| spellingShingle | OV Fedyk VO Sarzhevskii DA Fedorenko VYa Mel’nichenko YuN Dubinina NE Mochkin EG Smirnova DS Kolesnikova AE Bannikova Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis Клиническая онкогематология lymphoproliferative disorders autologous transplantation mobilization of peripheral blood stem cells autoimmune diseases multiple sclerosis |
| title | Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis |
| title_full | Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis |
| title_fullStr | Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis |
| title_full_unstemmed | Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis |
| title_short | Comparative Efficacy Analysis of Mobilization and Collection of Autologous Hematopoietic Stem Cells in Patients with Lymphoproliferative Disorders and Multiple Sclerosis |
| title_sort | comparative efficacy analysis of mobilization and collection of autologous hematopoietic stem cells in patients with lymphoproliferative disorders and multiple sclerosis |
| topic | lymphoproliferative disorders autologous transplantation mobilization of peripheral blood stem cells autoimmune diseases multiple sclerosis |
| url | http://bloodjournal.ru/wp-content/uploads/2018/12/7-1.pdf |
| work_keys_str_mv | AT ovfedyk comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis AT vosarzhevskii comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis AT dafedorenko comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis AT vyamelnichenko comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis AT yundubinina comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis AT nemochkin comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis AT egsmirnova comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis AT dskolesnikova comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis AT aebannikova comparativeefficacyanalysisofmobilizationandcollectionofautologoushematopoieticstemcellsinpatientswithlymphoproliferativedisordersandmultiplesclerosis |